Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Data Published Shows Efficiency and Accuracy of Gene Expression Assay Technology

Published: Tuesday, October 03, 2006
Last Updated: Thursday, October 12, 2006
Bookmark and Share
The study examined the feasibility of obtaining higher throughput results using the quantitative Nuclease Protection Assay method.

HTG Inc. has announced results from a study measuring gene expression on marker genes have been published in the August 2006 issue of Toxicology in Vitro.

The study examined the feasibility of obtaining higher throughput results using the quantitative Nuclease Protection Assay (qNPAT) method versus the standard PCR-based testing approach in testing 12 specific gene markers of drug-induced phospholipidosis on HepG2 cells.

The published data show that the in vitro screening assay for compound-induced phospholipidosis should be transferable from a PCR-based assay to HTG's qNPA, a higher throughput method.

Hiroshi Sawada, Takeda Pharmaceutical Company Limited in Osaka, Japan is the lead author of the article.

The article entitled, "Improved Toxicogenomic Screening for Drug-Induced Phospholipidosis Using a Multiplexed Quantitative Gene Expression ArrayPlate assay," reports outcomes from a follow-on study to a toxicogenomics analysis evaluated in previous research that enables researchers to identify sets of gene markers for various toxic conditions.

These findings published in Toxicology in Vitro, the official journal of the European Society of Toxicology in Vitro, confirm the qNPA approach is beneficial in setting up toxicogenomics-based assay systems to further evaluate these gene markers.

The qNPA was tested on the following measures: sensitivity, repeatability and correlation.

Results demonstrated the expression of mRNA for all target genes was detected at quantifiable levels, the signal intensities and fold change values of each marker gene were highly repeatable and there was a high correlation between results gained from the qNPA and real-time PCR assays.

"We are thrilled Takeda recognizes the qNPA technology as a useful, investigative tool in evaluating toxicogenomics analysis," said Bill Radany, president and CEO, HTG.

"HTG is enabling high-throughput screening for mainstream drug discovery and is a cost effective alternative to PCR."

HTG's ArrayPlate qNPAT technology is used to carry out quantitative multiplexed, gene-based drug discovery programs, including target validation, HTS lead optimization, metabolism, toxicology and clinical development.

HTG's ArrayPlate lysis-only quantitative Nuclease Protection Assay (qNPAT) platform is designed to allow scientists to test any sample while avoiding the need for extraction or target amplification.

The platform is designed to provide high-quality quantitative test results, including QSAR-quality dose response data and EC50's.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!